Need Assistance?
  • US & Canada:
    +
  • UK: +

AdTx1

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

AdTx1 is a high affinity, selective and non-competitive α1A adrenoceptor antagonist with Ki value of 0.35 nM. It is a 65 amino-acid peptide originally isolated from the venom of the green mamba. It is stabilized by four disulfide bridges and belongs to the family of the three-finger-fold peptide. It displays no significant activity against a range of other GPCRs. It antagonizes effects of phenylephrine on intra-urethral pressure in rats and on isolated rabbit prostate muscle in vitro. It is used as a potent relaxant of smooth muscles.

Category
Peptide Inhibitors
Catalog number
BAT-010267
Molecular Formula
C310H481N87O100S8
Molecular Weight
7283.22
Synonyms
ρ-Da1a
Appearance
Lyophilized Solid
Purity
>98%
Sequence
LTC(1)VTSKSIFGITTEDC(2)PDGQNLC(1)FKRRHYVVPKIYDSTRGC(2)AATC(3)PIPENYDSIHC(3)C(4)KTDKC(4)NE
Storage
Store at -20°C
Solubility
Soluble in water
1. Crystallization of recombinant green mamba ρ-Da1a toxin during a lyophilization procedure and its structure determination
Denis Servent,Nicolas Gilles,Arhamatoulaye Maïga,Gilles Mourier,Enrico Adriano Stura,Alain Lorphelin,Laurent Bellanger,Charles Marchetti,Laura Vera Acta Crystallogr Sect F Struct Biol Cryst Commun . 2013 Jun;69(Pt 6):704-9. doi: 10.1107/S1744309113011470.
ρ-Da1a toxin from eastern green mamba (Dendroaspis angusticeps) venom is a polypeptide of 65 amino acids with a strong affinity for the G-protein-coupled α(1A)-adrenoceptor. This neurotoxin has been crystallized from resolubilized lyophilized powder, but the best crystals grew spontaneously during lyophilization. The crystals belonged to the trigonal space group P3(1)21, with unit-cell parameters a = b = 37.37, c = 66.05 Å, and diffracted to 1.95 Å resolution. The structure solved by molecular replacement showed strong similarities to green mamba muscarinic toxins.
2. Effects of ρ-Da1a a peptidic α(1) (A) -adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats
N Gilles,S Palea,P Lluel,H Botto,A Maiga,P Camparo,M Rekik,C Rouget,M Guérard,V Guilloteau,P Rischmann Br J Pharmacol . 2013 Feb;168(3):618-31. doi: 10.1111/j.1476-5381.2012.02231.x.
Background and purpose:ρ-Da1a, a 65 amino-acid peptide, has subnanomolar affinity and high selectivity for the human α(1) (A) -adrenoceptor subtype. The purpose of this study was to characterize the pharmacological effects of ρ-Da1a on prostatic function, both in vivo and in vitro.Experimental approach:ρ-Da1a was tested as an antagonist of adrenaline-induced effects on COS cells transfected with the human α(1) (A) -adrenoceptor as well as on human isolated prostatic adenoma obtained from patients suffering from benign prostatic hyperplasia. Moreover, we compared the effects of ρ-Da1a and tamsulosin on phenylephrine (PHE)-induced increases in intra-urethral (IUP) and arterial pressures (AP) in anaesthetized rats, following i.v. or p.o. administration.Key results:On COS cells expressing human α(1) (A) -adrenoceptors and on human prostatic strips, ρ-Da1a inhibited adrenaline- and noradrenaline-induced effects. In anaesthetized rats, ρ-Da1a and tamsulosin administered i.v. 30 min before PHE significantly antagonized the effects of PHE on IUP. The pK(B) values for tamsulosin and ρ-Da1a for this effect were similar. With regards to AP, ρ-Da1a only reduced the effect of PHE on AP at the lowest dose tested (10 μg·kg(-1) ), whereas tamsulosin significantly reduced PHE effects at doses between 10 and 150 μg·kg(-1) .Conclusions and implications:ρ-Da1a exhibited a relevant effect on IUP and a small effect on AP. In contrast, tamsulosin antagonized the effects of PHE on both IUP and AP. We conclude that ρ-Da1a is more uroselective than tamsulosin. ρ-Da1a is the most selective peptidic antagonist for α(1A) -adenoceptors identified to date and could be a new treatment for various urological diseases.
3. Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor
A Ménez,C Marquer,R Thai,D Servent,L Quinton,P Lluel,J Ciolek,T Magnin,G Masuyer,C Fruchart-Gaillard,N Gilles,S Palea,A Maiga,J Chamot-Rooke,G Mourier,R Wagner,E Girard,J Molgó,M Larregola,M Rekik Br J Pharmacol . 2010 Jan 1;159(2):316-25. doi: 10.1111/j.1476-5381.2009.00532.x.
Background and purpose:Venoms are a rich source of ligands for ion channels, but very little is known about their capacity to modulate G-protein coupled receptor (GPCR) activity. We developed a strategy to identify novel toxins targeting GPCRs.Experimental approach:We studied the interactions of mamba venom fractions with alpha(1)-adrenoceptors in binding experiments with (3)H-prazosin. The active peptide (AdTx1) was sequenced by Edman degradation and mass spectrometry fragmentation. Its synthetic homologue was pharmacologically characterized by binding experiments using cloned receptors and by functional experiments on rabbit isolated prostatic smooth muscle.Key results:AdTx1, a 65 amino-acid peptide stabilized by four disulphide bridges, belongs to the three-finger-fold peptide family. It has subnanomolar affinity (K(i)= 0.35 nM) and high specificity for the human alpha(1A)-adrenoceptor subtype. We showed high selectivity and affinity (K(d)= 0.6 nM) of radio-labelled AdTx1 in direct binding experiments and revealed a slow association constant (k(on)= 6 x 10(6).M(-1).min(-1)) with an unusually stable alpha(1A)-adrenoceptor/AdTx1 complex (t(1/2diss)= 3.6 h). AdTx1 displayed potent insurmountable antagonism of phenylephrine's actions in vitro (rabbit isolated prostatic muscle) at concentrations of 10 to 100 nM.Conclusions and implications:AdTx1 is the most specific and selective peptide inhibitor for the alpha(1A)-adrenoceptor identified to date. It displays insurmountable antagonism, acting as a potent relaxant of smooth muscle. Its peptidic nature can be exploited to develop new tools, as a radio-labelled-AdTx1 or a fluoro-labelled-AdTx1. Identification of AdTx1 thus offers new perspectives for developing new drugs for treating benign prostatic hyperplasia.
Online Inquiry
Verification code
Inquiry Basket